Recent knowledge in favor of remdesivir (GS-5734) as a therapeutic option for the COVID-19 infections

Link to article at PubMed

J Infect Public Health. 2021 Feb 20;14(5):655-660. doi: 10.1016/j.jiph.2021.02.006. Online ahead of print.


The management of SARS-CoV-2 has not yet been clearly determined and is based on potential therapies evaluated during the SARS-CoV and MERS-CoV outbreaks. An emerging potential therapeutic approach currently being evaluated in numerous clinical trials is the remdesivir agent, which acts on COVID-19 by interfering with key steps in the virus replication cycle. It is considered a therapeutic option to be evaluated against COVID-19, based on data on its in vitro and in vivo activity against MERS-CoV and SARS-CoV coronaviruses. In this work, we provide an overview of remdesivir's discovery, mechanism of action, and the current studies exploring its clinical effectiveness. Recommendations for its use against COVID-19 infection are also summarized.

PMID:33857725 | PMC:PMC8039503 | DOI:10.1016/j.jiph.2021.02.006

Leave a Reply

Your email address will not be published.